Wockhardt Liquidates US Generics Units to Fuel Antibiotic and Insulin Innovation

Chapter 7 liquidation of its Delaware subsidiaries clears capital for a planned August NDA filing for Zaynich in support of Wockhardt’s shift toward higher-margin research-led pharmaceuticals.